- Home
- ICCC vs SURG Comparison
ICCC vs SURG Comparison
Compare ICCC & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- SURG
- Stock Information
- Founded
- ICCC 1982
- SURG 2006
- Country
- ICCC United States
- SURG United States
- Employees
- ICCC N/A
- SURG N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- SURG Advertising
- Sector
- ICCC Health Care
- SURG Consumer Discretionary
- Exchange
- ICCC Nasdaq
- SURG Nasdaq
- Market Cap
- ICCC 55.5M
- SURG 56.8M
- IPO Year
- ICCC 1987
- SURG N/A
- Fundamental
- Price
- ICCC $6.16
- SURG $2.87
- Analyst Decision
- ICCC
- SURG Strong Buy
- Analyst Count
- ICCC 0
- SURG 1
- Target Price
- ICCC N/A
- SURG $9.50
- AVG Volume (30 Days)
- ICCC 19.4K
- SURG 115.4K
- Earning Date
- ICCC 11-13-2025
- SURG 11-13-2025
- Dividend Yield
- ICCC N/A
- SURG N/A
- EPS Growth
- ICCC N/A
- SURG N/A
- EPS
- ICCC 0.20
- SURG N/A
- Revenue
- ICCC $28,274,756.00
- SURG $36,461,935.00
- Revenue This Year
- ICCC N/A
- SURG $20.20
- Revenue Next Year
- ICCC N/A
- SURG $121.54
- P/E Ratio
- ICCC $31.10
- SURG N/A
- Revenue Growth
- ICCC 21.75
- SURG N/A
- 52 Week Low
- ICCC $3.38
- SURG $1.05
- 52 Week High
- ICCC $7.60
- SURG $3.47
- Technical
- Relative Strength Index (RSI)
- ICCC 46.17
- SURG 54.04
- Support Level
- ICCC $6.06
- SURG $2.57
- Resistance Level
- ICCC $6.75
- SURG $2.95
- Average True Range (ATR)
- ICCC 0.36
- SURG 0.16
- MACD
- ICCC -0.04
- SURG 0.01
- Stochastic Oscillator
- ICCC 15.31
- SURG 53.64
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.